Valerie P. J. Saw
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Valerie P. J. Saw has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
John K.G. Dart
†Moorfields Eye Hospital, London, United Kingdom
4 shared publicationsGrazyna Galatowicz
Department of Ocular Biology and Therapeutics, University College London Institute of Ophthalmology, London, United Kingdom
3 shared publicationsJulie T. Daniels
Department of Ocular Biology and Therapeutics, University College London Institute of Ophthalmology, London, United Kingdom
3 shared publicationsVirginia L. Calder
Department of Ocular Biology and Therapeutics, University College London Institute of Ophthalmology, London, United Kingdom
3 shared publicationsIfeoma Offiah
Department of Ocular Biology and Therapeutics, University College London Institute of Ophthalmology, London, United Kingdom
2 shared publications- Robin John Dart
Department of Gastroenterology Guy's and St Thomas Foundation Trust London UK
2 shared publications
Latest Publications
- 16 June 2017
- Published by Springer Nature in Eye
- Vol. 31 (9) , 1380-1381
Response to: 'An alternative method for upper and lower conjunctival fornix measurement'
- 16 June 2017
- Published by Springer Nature in Eye
- Vol. 31 (9) , 1380-1381
Response to: 'An alternative method for upper and lower conjunctival fornix measurement'
- 5 April 2014
- Published by Springer Nature
- p. 19-39
Immune Modulation in Ocular Mucous Membrane Pemphigoid
- 5 April 2014
- Published by Springer Nature
- p. 19-39
Immune Modulation in Ocular Mucous Membrane Pemphigoid
- 1 January 2011
- Published by Elsevier in The American Journal of Pathology
- Vol. 178 (1) , 187-197
Profibrotic Phenotype of Conjunctival Fibroblasts from Mucous Membrane Pemphigoid
- 1 January 2011
- Published by Elsevier in The American Journal of Pathology
- Vol. 178 (1) , 187-197
Profibrotic Phenotype of Conjunctival Fibroblasts from Mucous Membrane Pemphigoid
- 1 December 2009
- Published by Elsevier in The American Journal of Pathology
- Vol. 175 (6) , 2406-2415
Conjunctival Interleukin-13 Expression in Mucous Membrane Pemphigoid and Functional Effects of Interleukin-13 on Conjunctival Fibroblasts in Vitro
- 1 December 2009
- Published by Elsevier in The American Journal of Pathology
- Vol. 175 (6) , 2406-2415
Conjunctival Interleukin-13 Expression in Mucous Membrane Pemphigoid and Functional Effects of Interleukin-13 on Conjunctival Fibroblasts in Vitro
- Open Access
- 1 November 2009
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 50 (11) , 5310-5317
Tumor Necrosis Factor-α in Ocular Mucous Membrane Pemphigoid and Its Effect on Conjunctival Fibroblasts
Purpose.: First, to determine whether tumor necrosis factor-(TNF)-α is expressed in the conjunctiva of ocular mucous membrane pemphigoid (MMP) and the consequences of systemic immunosuppressive treatment on this expression. Second, to investigate the in vitro effects of TNFα on human conjunctival fibroblasts. Methods.: The expression of TNFα in conjunctival tissues of patients with actively inflamed ocular MMP (n = 10), patients with clinically noninflamed ocular MMP after systemic immunosuppressive treatment (n = 10), and normal subjects (n = 10) was studied by immunohistochemistry. The effect of TNFα on functional assays of human conjunctival fibroblast activity were investigated, including migration, collagen lattice contraction, matrix metalloproteinase (mmp), and tissue inhibitor of matrix metalloproteinase (timp) secretion, proliferation, and surface expression of HLA-DR, ICAM, CD80, CD86, CD40, CD40-ligand. Results.: In active ocular MMP, TNFα is expressed by a large number of stromal infiltrating cells (234 cells/mm2), and although the level of stromal TNFα expression is significantly reduced after immunosuppressive treatment (90 cells/mm2), these levels are still significantly elevated compared with normal conjunctiva (10 cells/mm2, P < 0.05). TNFα stimulates increased migration by conjunctival fibroblasts (P < 0.001), increased production of mmp-9 (P = 0.01), decreased production of timp-2 (P = 0.01) and timp-4 (P = 0.04), and upregulated expression of CD40 and ICAM (P = 0.04). No significant effects of TNFα on fibroblast proliferation or collagen lattice contraction were detected. Conclusions.: Increased conjunctival expression of TNFα in ocular MMP suggests that systemic TNFα antagonists are likely to be effective in controlling severe disease unresponsive to conventional systemic immunosuppression. Residual TNFα expression persists in clinically noninflamed disease. TNFα appears to have profibrotic and proinflammatory effects on human conjunctival fibroblasts.
- 1 November 2009
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 50 (11) , 5310-5317
Open AccessTumor Necrosis Factor-α in Ocular Mucous Membrane Pemphigoid and Its Effect on Conjunctival Fibroblasts
Purpose.: First, to determine whether tumor necrosis factor-(TNF)-α is expressed in the conjunctiva of ocular mucous membrane pemphigoid (MMP) and the consequences of systemic immunosuppressive treatment on this expression. Second, to investigate the in vitro effects of TNFα on human conjunctival fibroblasts. Methods.: The expression of TNFα in conjunctival tissues of patients with actively inflamed ocular MMP (n = 10), patients with clinically noninflamed ocular MMP after systemic immunosuppressive treatment (n = 10), and normal subjects (n = 10) was studied by immunohistochemistry. The effect of TNFα on functional assays of human conjunctival fibroblast activity were investigated, including migration, collagen lattice contraction, matrix metalloproteinase (mmp), and tissue inhibitor of matrix metalloproteinase (timp) secretion, proliferation, and surface expression of HLA-DR, ICAM, CD80, CD86, CD40, CD40-ligand. Results.: In active ocular MMP, TNFα is expressed by a large number of stromal infiltrating cells (234 cells/mm2), and although the level of stromal TNFα expression is significantly reduced after immunosuppressive treatment (90 cells/mm2), these levels are still significantly elevated compared with normal conjunctiva (10 cells/mm2, P < 0.05). TNFα stimulates increased migration by conjunctival fibroblasts (P < 0.001), increased production of mmp-9 (P = 0.01), decreased production of timp-2 (P = 0.01) and timp-4 (P = 0.04), and upregulated expression of CD40 and ICAM (P = 0.04). No significant effects of TNFα on fibroblast proliferation or collagen lattice contraction were detected. Conclusions.: Increased conjunctival expression of TNFα in ocular MMP suggests that systemic TNFα antagonists are likely to be effective in controlling severe disease unresponsive to conventional systemic immunosuppression. Residual TNFα expression persists in clinically noninflamed disease. TNFα appears to have profibrotic and proinflammatory effects on human conjunctival fibroblasts.
- 24 September 2008
- Published by BMJ in British Journal of Ophthalmology
- Vol. 92 (10) , 1403-1410
Cicatrising conjunctivitis with anti-basement membrane autoantibodies in ectodermal dysplasia
Aims: To report circulating and mucosa-deposited anti-basement membrane zone autoantibodies in a series of six ectodermal dysplasia patients with severe bilateral cicatrising conjunctivitis and blindness due to both corneal disease and intractable surface inflammation. We also report clinical improvement with steroid-sparing systemic immunosuppression combined with clearance of bacterial colonisation. Methods: Conjunctival and buccal immunohistopathology, and serological analysis using a panel of epithelial basement membrane zone proteins including the bullous pemphigoid antigen 180 (BP180) were carried out as part of an ocular pemphigoid work-up in each patient. The degree of photophobia, conjunctival inflammation and visual acuity were monitored to evaluate the response to immunosuppression. The mean duration of follow-up was 31 (SD 6) months. Results: Four of the six patients showed positive immunopathology: direct immunofluorescence testing of the conjunctiva in one patient demonstrated linear IgA deposition along the basement membrane zone, and IgG and IgM in the buccal mucosa of another patient. Circulating autoantibodies to BP180 were detected in two other patients. Treatment with systemic immunosuppression, combined with clearance of bacterial colonisation, reduced the severity of photophobia and degree of conjunctival inflammation in 5/6 (83%) patients. Conclusions: Systemic immunosuppression, used as steroid-sparing therapy, combined with clearance of bacterial colonisation can control inflammation and disabling photophobia, and allow improvement in vision, in a subgroup of ectodermal dysplasia patients who have severe cicatrising conjunctivitis which shares clinical and immunopathological features with ocular mucous membrane pemphigoid.
- 24 September 2008
- Published by BMJ in British Journal of Ophthalmology
- Vol. 92 (10) , 1403-1410
Cicatrising conjunctivitis with anti-basement membrane autoantibodies in ectodermal dysplasia
Aims: To report circulating and mucosa-deposited anti-basement membrane zone autoantibodies in a series of six ectodermal dysplasia patients with severe bilateral cicatrising conjunctivitis and blindness due to both corneal disease and intractable surface inflammation. We also report clinical improvement with steroid-sparing systemic immunosuppression combined with clearance of bacterial colonisation. Methods: Conjunctival and buccal immunohistopathology, and serological analysis using a panel of epithelial basement membrane zone proteins including the bullous pemphigoid antigen 180 (BP180) were carried out as part of an ocular pemphigoid work-up in each patient. The degree of photophobia, conjunctival inflammation and visual acuity were monitored to evaluate the response to immunosuppression. The mean duration of follow-up was 31 (SD 6) months. Results: Four of the six patients showed positive immunopathology: direct immunofluorescence testing of the conjunctiva in one patient demonstrated linear IgA deposition along the basement membrane zone, and IgG and IgM in the buccal mucosa of another patient. Circulating autoantibodies to BP180 were detected in two other patients. Treatment with systemic immunosuppression, combined with clearance of bacterial colonisation, reduced the severity of photophobia and degree of conjunctival inflammation in 5/6 (83%) patients. Conclusions: Systemic immunosuppression, used as steroid-sparing therapy, combined with clearance of bacterial colonisation can control inflammation and disabling photophobia, and allow improvement in vision, in a subgroup of ectodermal dysplasia patients who have severe cicatrising conjunctivitis which shares clinical and immunopathological features with ocular mucous membrane pemphigoid.
- 1 July 2008
- Published by Elsevier in The Ocular Surface
- Vol. 6 (3) , 128-142
Ocular Mucous Membrane Pemphigoid: Diagnosis and Management Strategies
- 1 July 2008
- Published by Elsevier in The Ocular Surface
- Vol. 6 (3) , 128-142
Ocular Mucous Membrane Pemphigoid: Diagnosis and Management Strategies
- Open Access
- 1 May 2008
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 126 (5) , 734-735
Infliximab Therapy for Aggressive Mooren Ulceration
Mooren ulceration is an uncommon corneal autoimmune disease that can lead to blindness. We describe a patient with aggressive disease in whom inflammatory control was only achieved after infusion of a tumor necrosis factor α antagonist, infliximab.
- 1 May 2008
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 126 (5) , 734-735
Open AccessInfliximab Therapy for Aggressive Mooren Ulceration
Mooren ulceration is an uncommon corneal autoimmune disease that can lead to blindness. We describe a patient with aggressive disease in whom inflammatory control was only achieved after infusion of a tumor necrosis factor α antagonist, infliximab.
- 1 February 2008
- Published by Elsevier in Ophthalmology
- Vol. 115 (2) , 253-261.e1
Immunosuppressive Therapy for Ocular Mucous Membrane Pemphigoid
- 1 February 2008
- Published by Elsevier in Ophthalmology
- Vol. 115 (2) , 253-261.e1
Immunosuppressive Therapy for Ocular Mucous Membrane Pemphigoid
- 21 February 2007
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (8) , 1042-1047
Amniotic membrane transplantation for ocular disease: a review of the first 233 cases from the UK user group
Amniotic membrane transplantation (AMT), as a new tool in the armamentarium of therapies available for ocular surface problems, became widely available in the UK in 1998. This study evaluates the indications for treatment, the surgical procedures used, and the results of a subset of the first AMT cases carried out by the group using this nationally available supply. This user group model provides data which is different from that obtained from uncontrolled case series, or clinical trials, and may be more representative of the outcomes that can be expected when a procedure becomes widely available. The first 233 AMTs, performed by the UK user group, were evaluated by audit and outcomes were assessed at 3 months. Of the 233 transplants, there were 126 (54.1%) valid outcome returns: the outcome for persistent epithelial defects was a healed and stable surface in 11/35 (31.4%, 95% CI 16.9 to 49.3); for chemical/thermal injuries, a healed uninflamed eye with clear cornea in 5/18 (27.8%, 95% CI 9.7 to 53.4); for bullous keratopathy a pain-free, stable surface without bullae in 4/18 (22.2%, 95% CI 6.4 to 47.6); for ocular surface reconstruction, an epithelialised uninflamed conjunctiva without scarring in 12/23 (52.2%, 95% CI 30.6 to 73.2); and for limbal stem cell deficiency, a corneal phenotype in 4/7 (57.1%). The operative technique least associated with failure was use of a bandage contact lens at the end of the procedure (OR 0.19, 95% CI 0.06 to 0.59, p = 0.004). Previous treatment with topical steroids was significantly associated with failure (OR 5.70, 95% CI 1.77 to 18.43, p = 0.004). Although the outcome criteria used in this study were stringent, and the follow-up duration was short, the results of AMT by this user group were generally less favourable than those of previously reported case series. Controlled clinical trials would improve the quality of evidence for use of amniotic membrane in ocular disease.
- 21 February 2007
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (8) , 1042-1047
Amniotic membrane transplantation for ocular disease: a review of the first 233 cases from the UK user group
Amniotic membrane transplantation (AMT), as a new tool in the armamentarium of therapies available for ocular surface problems, became widely available in the UK in 1998. This study evaluates the indications for treatment, the surgical procedures used, and the results of a subset of the first AMT cases carried out by the group using this nationally available supply. This user group model provides data which is different from that obtained from uncontrolled case series, or clinical trials, and may be more representative of the outcomes that can be expected when a procedure becomes widely available. The first 233 AMTs, performed by the UK user group, were evaluated by audit and outcomes were assessed at 3 months. Of the 233 transplants, there were 126 (54.1%) valid outcome returns: the outcome for persistent epithelial defects was a healed and stable surface in 11/35 (31.4%, 95% CI 16.9 to 49.3); for chemical/thermal injuries, a healed uninflamed eye with clear cornea in 5/18 (27.8%, 95% CI 9.7 to 53.4); for bullous keratopathy a pain-free, stable surface without bullae in 4/18 (22.2%, 95% CI 6.4 to 47.6); for ocular surface reconstruction, an epithelialised uninflamed conjunctiva without scarring in 12/23 (52.2%, 95% CI 30.6 to 73.2); and for limbal stem cell deficiency, a corneal phenotype in 4/7 (57.1%). The operative technique least associated with failure was use of a bandage contact lens at the end of the procedure (OR 0.19, 95% CI 0.06 to 0.59, p = 0.004). Previous treatment with topical steroids was significantly associated with failure (OR 5.70, 95% CI 1.77 to 18.43, p = 0.004). Although the outcome criteria used in this study were stringent, and the follow-up duration was short, the results of AMT by this user group were generally less favourable than those of previously reported case series. Controlled clinical trials would improve the quality of evidence for use of amniotic membrane in ocular disease.